Negative Pressure Wound Therapy for Breast Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
London Health Sciences Centre, London, Canada
Breast Cancer+3 More
Negative Pressure Wound Therapy - Device
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

The current study is a single center randomized control trial that will examine the effect of closed incision negative pressure wound therapy (ciNPT) versus conventional dressing on abdominal incision in a deep inferior epigastric perforator (DIEP) flap based reconstruction. Patients will be followed by 30 days post-operatively to compare outcomes including the rate of surgical site infection, seroma, and the scar quality.

Eligible Conditions

  • Breast Cancer
  • Wound Dehiscence
  • Surgical Site Infections

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: 30 days after operation

30 days after operation
Postoperative Surgical Site Infection (SSI)
The rate of hematoma diagnosis
The rate of seroma diagnosis
The rate of wound dehiscence

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

Standard Dressing
1 of 2
Negative Pressure Wound Therapy
1 of 2
Active Control
Experimental Treatment

520 Total Participants · 2 Treatment Groups

Primary Treatment: Negative Pressure Wound Therapy · No Placebo Group · N/A

Negative Pressure Wound Therapy
Device
Experimental Group · 1 Intervention: Negative Pressure Wound Therapy · Intervention Types: Device
Standard Dressing
Device
ActiveComparator Group · 1 Intervention: Negative Pressure Wound Therapy · Intervention Types: Device
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Negative Pressure Wound Therapy
2019
N/A
~1010

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 30 days after operation

Trial Background

Tanya DeLyzer, Principal Investigator
Principal Investigator
Western University, Canada
Closest Location: London Health Sciences Centre · London, Canada
Photo of london health sciences centre  1Photo of london health sciences centre  2
2011First Recorded Clinical Trial
4 TrialsResearching Breast Cancer
340 CompletedClinical Trials

Eligibility Criteria

Age 18+ · Female Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are undergoing immediate or delayed reconstruction of the breast following mastectomy.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.